Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80
Organisation › Details

Amphista Therapeutics Ltd.

Amphista Therapeutics is a biopharmaceutical company creating first-in-class therapeutics that help harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins. The company’s pipeline of novel small molecules that cause targeted protein degradation (TPD) is focused on challenging diseases including cancer. Amphista is a spin-out of renowned TPD expert Professor Alessio Ciulli’s labs at the University of Dundee, and is based in BioCity Glasgow, Scotland. The company is funded by leading life science investors including Advent Life Sciences, the European Investment Fund, the Scottish Investment Bank, and BioMotiv. *


Period Start 2017-12-20 established (s-off
  Predecessor University of Dundee
Product Industry protein degradation drug
Persons Person Thompson, Nicola (Nicki) (Amphista Therapeutics 201906– CEO before Nanna Therapeutics + VirionHealth + Phico Tx)
  Person 2 Ciulli, Alessio (Univ Dundee 201607 Associate Professor of Chemical + Structural Biology)
  Street Bo’Ness Road
BioCity Glasgow, Chapelhall, Motherwell
  City ML1 5UH Newhouse, Lanarkshire
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: Amphista Therapeutics Ltd.. (4/7/20). "Press Release: Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer". Glasgow.
Record changed: 2021-03-18


Picture [iito] Made Without Love 650x80px

More documents for Amphista Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px

» top